OncoDxRx Demonstrating the Power of Its One-Of-A-Kind RNA Technologies to Go Beyond Diagnostics
With a complete clinical picture via OcoDxRx’s blood RNA technology, the process and precision of treating cancer is being redefined. OncoDxRx is able to gain multilayer insights to provide the most accurate and earliest detection, tailor better treatment regimen, and thus deliver more precise and preventive medicine. It is the blood RNA knowhow and trade secret that enable OncoDxRx to establish treatment decisions, better prognosis, and therapeutic approaches — laying the roadmap to personalized treatment options.
RNA serves not only as translators of genetic information, but also subjects of gene expression regulation. Compared with DNA mutations that are associated with tumor cells, RNA biomarkers possess higher sensitivity and specificity beyond tumor itself, and have the advantage of providing dynamic and deeper insights into tempo-spatial distribution and regulatory processes including tumor clonal evolution, changes in tumor microenvironment, immune responses, and blood vessel epithelium function. All of these subtle physiological changes are prerequisite for precancerous lesion formation that can only be revealed by RNA-based technology. Further, RNA existed as multiple copies with various spliced variants, providing a much higher chance to be detected in blood than DNA. PCR also enables traces of RNA sequences to be amplified and thus captured specifically with high sensitivity. Most importantly, RNA transcripts usually have stable secondary and tertiary structures, and complexed with proteins or lipids, thereby protecting them from degradation in circulation, making RNA a perfect biomarker for cancer early detection, minimal residual disease (MRD), treatment selection and RNA therapeutics in OncoDxRx’s innovative portfolio.
OncoDxRx has eight transformative pipelines currently are in different phases of research and development, validation and commercialization, with PGA (Patient-derived Gene expression-informed Anti-cancer drug efficacy) assays to be launched shortly. Other technologies include MRD, multi-cancer early detection as well as DNA repair activity measurement and cancer drug discovery. “OncoDxRx will thus secure its forefront position to deal with cancer patients in all stages, whether in the context of cancer screening and prevention or in the context of treatment selection, recurrence monitoring or drug discovery.” The company said in the statement.
Follow us on Linkedin:
